pH-Responsive Ionizable Lipids for Safer Nucleic Acid Transfection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nucleic acid delivery technologies, particularly those using cationic lipids like DODAC, DOTMA, and DOTAP, are too toxic for clinical applications, and there is a need for more clinically relevant transfection lipids to efficiently deliver genetic material to living cells.
Innovation Solution
Development of ionizable lipids with specific chemical structures and formulations, including compounds of formulas (I), (II), and (III), which transition from neutral to cationic at lower pH, allowing safe and effective delivery of nucleic acids in lipid nanoparticles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cationic lipids like DODAC, DOTMA, and DOTAP are used for nucleic acid delivery, then transfection efficiency is improved, but toxicity increases making them unsuitable for clinical applications
Solution Approach 1:
The patent applies parameter changes by modifying the lipid structure from permanently cationic to ionizable (pH-responsive). The ionizable lipids remain neutral at physiological pH (reducing toxicity) but become cationic at endosomal pH (improving transfection efficiency). This dynamic parameter change allows the same lipid to perform different functions in different cellular compartments.
Solution Approach 2:
The invention implements dynamics by creating lipids that dynamically change their charge state based on environmental pH. The ionizable lipids transition from uncharged at pH 7.4 (circulating blood) to charged at pH 5-6 (endosomes), enabling adaptive behavior that optimizes both safety during circulation and efficacy during cellular delivery.
2Object-affected harmful factors
If ionizable lipids are used to reduce toxicity, then safety for clinical applications is improved, but transfection efficiency must be maintained
Solution Approach 1:
The patent resolves this contradiction by changing the pH parameter that controls lipid charge. At physiological pH, lipids are neutral and non-toxic; at endosomal pH, lipids become cationic and facilitate nucleic acid delivery. This parameter-based switch maintains both safety and efficacy.
Solution Approach 2:
The ionizable lipid acts as an intermediary that mediates between the conflicting requirements of low toxicity and high transfection efficiency. The lipid's pH-dependent charge transition serves as a molecular switch that enables safe circulation followed by effective delivery, bridging the gap between safety and efficacy requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ionizable lipids achieve efficient transfection of cells with nucleic acids, enhancing gene expression and therapeutic efficacy while minimizing toxicity, suitable for clinical applications.
Implementation Method 1
ionizable lipids with specific chemical structures and formulations, including compounds of formulas (I), (II), and (III), which transition from neutral to cationic at lower pH
Data Source
AI summary
The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) where R1 features an amine group, particularly useful in the formulation of lipid particles including nucleic acid therapeutic agents, or proteins, or both, and for delivery of nucleic acid and protein therapeutics to cells in vivo or ex vivo, including anticancer and vaccine applications.